Adam Dagnall

Adam Dagnall's work experience includes serving as a Scientific Director at Envision Pharma Group since September 2022. Prior to that, they worked as a Scientific Director at Lucid Group from November 2020 to August 2022. Adam also served as a Principal Medical Writer at Watermeadow Medical, an Ashfield company, from March 2010 to November 2020. Their earlier role was as an Associate Program Manager at excerpta Medica BV-Adelphi Group from October 2007 to December 2009.

Adam Dagnall's education history begins at Ysgol John Bright from 1989 to 1996, where they pursued a general education in a currently undisclosed field of study. Adam then enrolled at The University of Manchester from 1996 to 2000, completing a Bachelor of Science (BSc) degree with second-class honors (Class 2:I) in Physiology. Following this, they attended the University of Oxford from 2000 to 2001, earning a Master of Science (MSc) in Neuroscience. Lastly, they continued their education at the University of Oxford from 2001 to 2007, obtaining a Doctor of Philosophy (DPhil) degree in the field of Functional and Expression studies on ProtocadherinX/Y.